

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

宜明昂科生物醫藥技術（上海）股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 1541)

I. POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON MAY 28, 2024

II. APPOINTMENT OF DIRECTOR

The board of directors (the “**Board**”) of ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (the “**Company**”) is pleased to announce the poll results of the annual general meeting (the “**AGM**”) held at Unit 15, 1000 Zhangheng Road, China (Shanghai) Pilot Free Trade Zone, Pudong New Area, Shanghai, PRC on May 28, 2024 at 9:30 a.m. The AGM was convened by the Board in accordance with the Company Law of the PRC and the Articles of Association, and was chaired by Dr. Tian Wenzhi, the chairman of the Board, the chief executive officer, the chief scientific officer and an executive Director of the Company.

References are made to the notice of the AGM and the circular of the AGM of the Company both dated April 30, 2024 (the “**Circular**”). Unless otherwise defined, terms used in this announcement shall have the same meanings as those defined in the Circular.

I. POLL RESULTS OF THE ANNUAL GENERAL MEETING

Attendance of the AGM

Shareholders holding an aggregate of 312,903,420 Shares (comprising 173,645,832 H Shares and 139,257,588 Unlisted Shares), representing approximately 83.6288% of the total issued Shares, attended the AGM either in person or by proxy.

Poll Results of Resolutions Proposed at the AGM

All proposed resolutions as set out in the notice of the AGM dated April 30, 2024 were taken by poll. The poll results are as follows:

ORDINARY RESOLUTIONS		Number of votes cast and approximate percentage of total number of votes (%)	
		FOR	AGAINST
1.	To consider and approve the work report of the board of directors of the Company (the “ Board ”) for the year 2023.	312,903,420 (100%)	0 (0%)
2.	To consider and approve the work report of the supervisory committee of the Company for the year 2023.	312,903,420 (100%)	0 (0%)
3.	To consider and approve the annual report of the Company for the year 2023.	312,903,420 (100%)	0 (0%)
4.	To consider and approve the final financial report of the Company for the year 2023 and the financial budget report of the Company for the year 2024.	312,903,420 (100%)	0 (0%)
5.	To consider and approve the 2023 Profit Distribution Plan.	312,903,420 (100%)	0 (0%)
6.	To consider and approve the appointment of Ms. Guan Mei as an executive Director of the Company with the term of office, upon approval at the general meeting and ending upon the expiry of the term of appointment of the first session of the Board of the Company.	312,903,420 (100%)	0 (0%)
7.	To consider and approve the re-appointment of Deloitte Touche Tohmatsu as the auditor of the Company for the year 2024 and authorise the Board to determine its remuneration.	312,903,420 (100%)	0 (0%)
8.	To consider and approve the directors remuneration plan for the year 2024.	312,903,420 (100%)	0 (0%)
9.	To consider and approve the supervisors remuneration plan for the year 2024.	312,903,420 (100%)	0 (0%)

As more than half of the votes were casted in favour of the resolutions numbered 1 to 9, all the above resolutions were duly passed as ordinary resolutions.

SPECIAL RESOLUTION		FOR	AGAINST
10.	To consider and approve the granting of general mandate to the Board to issue new Shares.	309,508,530 (98.9150%)	3,394,890 (1.0850%)

As more than two-thirds of the votes were casted in favour of the resolution numbered 10, the above resolution was duly passed as a special resolution.

Notes:

- (a) As at the date of the AGM, the total number of issued Shares was 374,157,695 Shares (including 228,550,039 H Shares and 145,607,656 Unlisted Shares), which represented the total number of Shares entitling the Shareholders to attend and vote on the proposed resolutions at the AGM.
- (b) To the best knowledge, information and belief of the Company: (1) there were no shares entitling the holder to attend and abstain from voting in favour of the resolutions at the AGM as set out in rule 13.40 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”); (2) no shareholder of the Company was required under the Listing Rules to abstain from voting on the resolutions at the AGM; and (3) none of the shareholders of the Company has stated his/her/its intention in the Circular to vote against or to abstain from voting on any of the resolutions at the AGM.
- (c) The total number of issued Shares held by the Shareholders or their proxies who have attended the AGM and are entitled to vote is 312,903,420 Shares, representing approximately 83.6288% of the total number of issued Shares as at the date of the AGM.
- (d) The Company’s H share registrar, Computershare Hong Kong Investor Services Limited, acted as the scrutineer for the vote-taking at the AGM. One Supervisor of the Company and two Shareholders’ representatives were also responsible for the vote-taking at the AGM.
- (e) All directors of the Company attended the AGM in person or by electronic means.

II. APPOINTMENT OF DIRECTOR

Upon approval by the Shareholders at the AGM, Ms. Guan Mei (“**Ms Guan**”) was appointed as an executive Director of the first session of the Board. The term of office of Ms. Guan shall be commencing from May 28, 2024 until the expiration of the term of office of the first session of the Board. The biographical details of the aforesaid Director have been set out in the announcement of the Company (the “**Announcement**”) dated March 1, 2024 and Circular in accordance with Rule 13.51(2) of the Listing Rules. As of the date of this announcement, there is no change to such information.

By order of the Board
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Tian Wenzhi
Chairman and Executive Director

Shanghai, the PRC, May 28, 2024

As at the date of this announcement, the Board of Directors comprises (i) Dr. Tian Wenzhi, Mr. Li Song and Ms. Guan Mei as executive Directors; (ii) Dr. Xu Cong, Mr. Yu Zhihua and Mr. Yu Xiaoyong as non-executive Directors; and (iii) Dr. Zhenping Zhu, Dr. Kendall Arthur Smith and Mr. Yeung Chi Tat as independent non-executive Directors.